$100M Royalty Pharma-Zeland Deal Funds Rare Blood Disorder Drug
Event summary
- $100M deal funds Zealand Pharma's rusfertide, a potential first-in-class therapy for polycythemia vera.
- Royalty Pharma gains 1% royalty on future global net sales of rusfertide; Zealand retains 0.25% on sales above $1.5B.
- $50M paid at closing, remaining $50M due in one year.
- FDA set PDUFA goal date for rusfertide NDA in Q3 2026.
The big picture
This deal underscores Royalty Pharma's role as a key financier of late-stage biopharmaceutical innovations, particularly in rare diseases. The $100M investment reflects confidence in rusfertide's market potential and aligns with Zealand's Metabolic Frontier 2030 strategy. The transaction also highlights the growing trend of non-dilutive funding for specialty drug development.
What we're watching
- Regulatory Timeline
- Whether the FDA approval process for rusfertide stays on track for Q3 2026.
- Commercialization Strategy
- How Takeda executes global commercialization of rusfertide post-approval.
- Royalty Performance
- The pace at which rusfertide achieves $1.5B in sales, triggering Zealand's retained royalty.
Related topics